Dr Koby Stav from the Neurourology Division, Department of Urology, Assaf Harofeh Medical Center, presented the results of the study named “Safety and feasibility of intravesical instillation of botulinum toxin A in a novel hydrogel-based slow release delivery system in PBS/IC patients: A pilot study”.
Conclusions of this study showed that intravesical instillation of TCGel+BTX was:
- Well tolerated
- Appears generally safe
- Associated with apparent sustained reduction of PBS/IC symptoms for 3 months
Thought not placebo controlled, the results are encouraging and provide the basis for further exploration of the safety and efficacy of TCGel+BTX in a randomized placebo controlled trial.